Vanderbilt University Raises Holdings in Danaher Co. (NYSE:DHR)

Vanderbilt University grew its stake in Danaher Co. (NYSE:DHR) by 29.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 20,430 shares of the conglomerate’s stock after buying an additional 4,632 shares during the quarter. Danaher accounts for approximately 1.1% of Vanderbilt University’s portfolio, making the stock its 15th biggest position. Vanderbilt University’s holdings in Danaher were worth $5,680,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Good Life Advisors LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at approximately $217,000. Oak Thistle LLC acquired a new stake in Danaher in the second quarter valued at $363,000. Norden Group LLC purchased a new stake in Danaher during the 1st quarter worth about $4,151,000. Duality Advisers LP purchased a new position in shares of Danaher in the 1st quarter valued at about $5,573,000. Finally, Diversified Trust Co raised its position in shares of Danaher by 75.4% during the 2nd quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after acquiring an additional 1,874 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at approximately $11,501,145.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock worth $8,400,897 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on DHR shares. Royal Bank of Canada lowered their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. The Goldman Sachs Group boosted their price target on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Evercore ISI lifted their target price on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price for the company. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Price Performance

Danaher stock traded up $0.87 during midday trading on Monday, reaching $246.26. The company’s stock had a trading volume of 217,321 shares, compared to its average volume of 2,730,922. The stock’s 50 day simple moving average is $269.52 and its 200 day simple moving average is $260.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $182.40 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities research analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.